PR Newswire · Feb 2026
Announced a collaboration to build a Bay Area GMP manufacturing facility combining cyanobacteria-based oral biologics with Persist AI's robotic formulation and process-optimization platform.
Developing long-lasting drug formulations 50% faster
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Persist AI is a West Sacramento–based pharmaceutical manufacturing company building an AI- and robotics-driven platform to accelerate drug formulation development, with a particular focus on long-acting injectables and other hard-to-formulate drug products. Its offering combines cloud-accessible AI, robotic execution, and formulation expertise to help pharma teams move faster from molecule to product.
Primary product
Persist AI Cloud Lab / AI-driven robotic formulation platform
Founded
2022
Headquarters
890 Embarcadero Dr, West Sacramento, CA 95605, United States
Team size
20-30
Industry
Pharmaceutical Manufacturing
Sub-industry
AI-driven drug formulation, robotics-enabled pharmaceutical R&D, and preclinical formulation CRO/CDMO services
Offices
0 jobs at Persist AI
Check back later for new openings
Business model
Stage
Series A
Total raised
$16.6M
Latest round
Series A · May 2025
Latest amount
$12M
May 2025 · Spero Ventures
Aug 2023 · 2048 Ventures
Apr 2023 · Y Combinator
Mar 2023
Leadership
Co-Founder & CEO
Co-Founder & COO
Vice President of Business Development
Amjad Basha Mohammad
Head of Advanced Manufacturing
Brooke Kennedy
HR Director
The company presents itself as a small, cross-disciplinary team of scientists and engineers with a fast-moving, mission-driven culture centered on collaboration, automation, and accelerating patient access to better therapies.
Compensation
No public salary bands were found. A third-party LinkedIn-style employer snapshot shows a strong compensation sentiment signal (5.0/5.0 compensation subscore from 1 review), but that is not an explicit pay range.
Pricing
Custom-quote, B2B service model with tiered offerings: Persist AI Suite, Cloud Lab, and Full Service formulation development.
Differentiators
Technology
Customers
Competitors
Estimated revenue
About $3.8M ARR (2024 estimate); other third-party profiles place it in the $1M-$10M range.
Estimated monthly visits
3.3K
Traffic estimate as of Jul 2026
PR Newswire · Feb 2026
Announced a collaboration to build a Bay Area GMP manufacturing facility combining cyanobacteria-based oral biologics with Persist AI's robotic formulation and process-optimization platform.
Persist AI · Jun 2025
Official leadership expansion announcement adding Amjad Basha Mohammad as Head of Advanced Manufacturing and Ramesh Rachapudi as VP of Business Development.
PR Newswire · May 2025
Announced the Cloud Lab platform and a $12M Series A led by Spero Ventures with participation from strategic and venture investors.
PR Newswire · Aug 2024
Announced a collaboration to co-develop an AI-driven manufacturing process for long-acting injectable drugs with Nivagen Pharmaceuticals.
PR Newswire · Aug 2023
Announced a $4M seed financing round led by 2048 Ventures with participation from Innospark Ventures, Fellows Fund, Y Combinator, Pioneer Fund, and others.